Search
Ethiodized oil
go.drugbank.com/drugs/DB00965ApprovedInvestigationalEthiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. And although these esters are primarily as ethyl monoiodo...
Diethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawn(Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Prednisolone sodium metazoate
go.drugbank.com/drugs/DB05340InvestigationalATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon.
Guanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalHepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. … [L30260,L30275] Due to potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With
Brilliant green cation
go.drugbank.com/drugs/DB11279ApprovedVet approvedDue to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnEtoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigational[A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696] … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. … [A180739] Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.[A180724,A180727]
International brands: Xi Fu NiZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigationalZonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. … [L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan.
Synonyms: Benzo[d]isoxazol-3-yl-methanesulfonamide